Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It's Apples and Oranges

Kidney360. 2022 May 18;3(8):1442-1444. doi: 10.34067/KID.0000952022. eCollection 2022 Aug 25.

Authors

Silvia J Leon¹, Navdeep Tangri²

Affiliations

¹ Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Canada.
² Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.

No abstract available

Keywords: ACE inhibitors; ARB; MRA; RAAS inhibitor; chronic kidney disease; finerenone; hyperkalemia; potassium binders.

MeSH terms

Aldosterone
Angiotensin Receptor Antagonists / adverse effects
Angiotensins
Antihypertensive Agents
Humans
Hyperkalemia* / chemically induced
Mineralocorticoid Receptor Antagonists* / adverse effects
Mineralocorticoids
Renin

Substances

Angiotensin Receptor Antagonists
Angiotensins
Antihypertensive Agents
Mineralocorticoid Receptor Antagonists
Mineralocorticoids
Aldosterone
Renin